Literature DB >> 35460615

Deletion of LDLRAP1 Induces Atherosclerotic Plaque Formation, Insulin Resistance, and Dysregulated Insulin Response in Adipose Tissue.

Tani Leigh1, Tatsuo Kawai1, Kyle Preston1, Sheri Kelemen1, Rachael Okune1, Amanda St Paul1, Cali Corbett1, Amanda M Peluzzo1, Jun Yu1, Rosario G Scalia1, Michael V Autieri2.   

Abstract

Dyslipidemia, vascular inflammation, obesity, and insulin resistance often overlap and exacerbate each other. Mutations in low density lipoprotein receptor adaptor protein-1 (LDLRAP1) lead to LDLR malfunction and are associated with the autosomal recessive hypercholesterolemia disorder in humans. However, direct causality on atherogenesis in a defined preclinical model has not been reported. The objective of this study was to test the hypothesis that deletion of LDLRAP1 will lead to hypercholesteremia and atherosclerosis. LDLRAP1-/- mice fed a high-fat Western diet had significantly increased plasma cholesterol and triglyceride concentrations accompanied with significantly increased plaque burden compared with wild-type controls. Unexpectedly, LDLRAP1-/- mice gained significantly more weight compared with controls. Even on a chow diet, LDLRAP1-/- mice were insulin-resistant, and calorimetric studies suggested an altered metabolic profile. The study showed that LDLRAP1 is highly expressed in visceral adipose tissue, and LDLRAP1-/- adipocytes are significantly larger, have reduced glucose uptake and AKT phosphorylation, but have increased CD36 expression. Visceral adipose tissue from LDLRAP1-/- mice was hypoxic and had gene expression signatures of dysregulated lipid storage and energy homeostasis. These data are the first to indicate that lack of LDLRAP1 directly leads to atherosclerosis in mice and also plays an unanticipated metabolic regulatory role in adipose tissue. LDLRAP1 may link atherosclerosis and hypercholesterolemia with common comorbidities of obesity and insulin resistance.
Copyright © 2022 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35460615      PMCID: PMC9253916          DOI: 10.1016/j.ajpath.2022.03.014

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  64 in total

1.  Quantifying size and number of adipocytes in adipose tissue.

Authors:  Sebastian D Parlee; Stephen I Lentz; Hiroyuki Mori; Ormond A MacDougald
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.

Authors:  Joost Besseling; John J P Kastelein; Joep C Defesche; Barbara A Hutten; G Kees Hovingh
Journal:  JAMA       Date:  2015-03-10       Impact factor: 56.272

Review 3.  Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance.

Authors:  Joost J F P Luiken; Miranda Nabben; Dietbert Neumann; Jan F C Glatz
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-03-21       Impact factor: 5.187

4.  Attenuation of experimental atherosclerosis by interleukin-19.

Authors:  Stephen Ellison; Khatuna Gabunia; Sheri E Kelemen; Ross N England; Rosario Scalia; James M Richards; A Wayne Orr; Wayne Orr; James G Traylor; Thomas Rogers; William Cornwell; Lisa M Berglund; Isabel Goncalves; Maria F Gomez; Michael V Autieri
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-15       Impact factor: 8.311

Review 5.  The macrophage Ox-LDL receptor, CD36 and its association with type II diabetes mellitus.

Authors:  Sunaina Gautam; Monisha Banerjee
Journal:  Mol Genet Metab       Date:  2010-12-24       Impact factor: 4.797

6.  Oxidized LDL Is Associated With Metabolic Syndrome Traits Independently of Central Obesity and Insulin Resistance.

Authors:  Yamilee Hurtado-Roca; Hector Bueno; Antonio Fernandez-Ortiz; Jose Maria Ordovas; Borja Ibañez; Valentin Fuster; Fernando Rodriguez-Artalejo; Martin Laclaustra
Journal:  Diabetes       Date:  2016-12-19       Impact factor: 9.461

7.  CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes.

Authors:  Yeliz Angin; Laura K M Steinbusch; Peter J Simons; Sabrina Greulich; Nicole T H Hoebers; Kim Douma; Marc A M J van Zandvoort; Will A Coumans; Wino Wijnen; Michaela Diamant; D Margriet Ouwens; Jan F C Glatz; Joost J F P Luiken
Journal:  Biochem J       Date:  2012-11-15       Impact factor: 3.857

8.  Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects.

Authors:  Håkan K R Karlsson; Juleen R Zierath; Susan Kane; Anna Krook; Gustav E Lienhard; Harriet Wallberg-Henriksson
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

Review 9.  News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1.

Authors:  Bart van de Sluis; Melinde Wijers; Joachim Herz
Journal:  Curr Opin Lipidol       Date:  2017-06       Impact factor: 4.776

Review 10.  AKT ISOFORMS-AS160-GLUT4: The defining axis of insulin resistance.

Authors:  Medha Sharma; Chinmoy Sankar Dey
Journal:  Rev Endocr Metab Disord       Date:  2021-04-30       Impact factor: 6.514

View more
  2 in total

1.  Fatty acid metabolism-related genes are associated with flavor-presenting aldehydes in Chinese local chicken.

Authors:  Xiaoya Yuan; Huanxian Cui; Yuxi Jin; Wenjuan Zhao; Xiaojing Liu; Yongli Wang; Jiqiang Ding; Li Liu; Jie Wen; Guiping Zhao
Journal:  Front Genet       Date:  2022-08-12       Impact factor: 4.772

2.  Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study.

Authors:  Laura D'Erasmo; Antonina Giammanco; Patrizia Suppressa; Chiara Pavanello; Gabriella Iannuzzo; Alessia Di Costanzo; Daniele Tramontano; Ilenia Minicocci; Simone Bini; Anja Vogt; Kim Stewards; Jeanine Roeters Van Lennep; Stefano Bertolini; Marcello Arca
Journal:  Front Genet       Date:  2022-08-22       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.